Suppr超能文献

巴利昔替尼,一种组织蛋白酶 K 抑制剂,可刺激猴子的骨膜骨形成。

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.

机构信息

Think Bone Consulting, Inc, PO Box 1611, Langley, WA 98260, USA.

出版信息

Osteoporos Int. 2011 Dec;22(12):3001-11. doi: 10.1007/s00198-011-1529-x. Epub 2011 Feb 10.

Abstract

UNLABELLED

Balicatib, an inhibitor of the osteoclastic enzyme cathepsin K, was tested in ovariectomized monkeys, a model for osteoporosis. As expected, ovariectomy-induced bone mass changes were partially prevented by balicatib treatment. Bone turnover was significantly decreased at most sites, but unlike most bone resorption inhibitors, periosteal bone formation rates were increased.

INTRODUCTION

Selective inhibitors of the osteoclastic enzyme cathepsin K have potential in osteoporosis treatment. This study evaluated the efficacy of balicatib (AAE581), a novel inhibitor of human cathepsin K, on bone mass and dynamic histomorphometric endpoints in ovariectomized monkeys.

METHODS

Eighty adult female Macaca fascicularis underwent bilateral ovariectomies and were dosed twice daily by oral gavage with balicatib at 0, 3, 10, and 50 mg/kg for 18 months (groups O, L, M, H, respectively). Approximately 1 month after treatment initiation, the 50 mg/kg dose was decreased to 30 mg/kg. Twenty animals underwent sham-ovariectomies (group S). Bone mass was measured at 3-6 month intervals. At 18 months, vertebra and femur were collected for histomorphometry.

RESULTS

In both spine and femur, group O animals lost bone mineral density (BMD), and all other groups gained BMD between 0 and 18 months. In balicatib-treated animals, BMD change in the spine was intermediate between group S and O, with groups L and M significantly different from group O. In femur, all three doses of balicatib significantly increased BMD gain relative to group O, and group mean values were also higher than group S. Most histomorphometric indices of bone turnover in vertebra and femoral neck were significantly lower than group O with balicatib treatment, except that periosteal bone formation rates (Ps.BFR) were significantly higher. Ps.BFR in mid-femur was also significantly increased by treatment.

CONCLUSIONS

Balicatib partially prevented ovariectomy-induced changes in bone mass, inhibited bone turnover at most sites, and had an unexpected stimulatory effect on periosteal bone formation.

摘要

未加标签

巴利昔替尼是一种破骨细胞酶组织蛋白酶 K 的抑制剂,已在去卵巢猴子(骨质疏松症模型)中进行了测试。正如预期的那样,巴利昔替尼治疗部分预防了去卵巢引起的骨量变化。大多数部位的骨转换明显降低,但与大多数骨吸收抑制剂不同的是,骨膜骨形成率增加。

引言

选择性破骨细胞酶组织蛋白酶 K 抑制剂在骨质疏松症治疗中具有潜力。本研究评估了新型人组织蛋白酶 K 抑制剂巴利昔替尼(AAE581)对去卵巢猴子的骨量和动态组织形态计量学终点的疗效。

方法

80 只成年雌性恒河猴接受双侧卵巢切除术,并通过口服灌胃每天两次给予巴利昔替尼 0、3、10 和 50mg/kg,持续 18 个月(分别为 O、L、M、H 组)。治疗开始后约 1 个月,将 50mg/kg 剂量减少至 30mg/kg。20 只动物接受假手术卵巢切除术(S 组)。每隔 3-6 个月测量一次骨量。18 个月时,收集脊椎和股骨进行组织形态计量学分析。

结果

在脊椎和股骨中,O 组动物的骨密度(BMD)丢失,而其他所有组在 0 至 18 个月期间均获得 BMD。在巴利昔替尼治疗的动物中,脊椎的 BMD 变化处于 S 组和 O 组之间,L 组和 M 组与 O 组明显不同。在股骨中,巴利昔替尼的三种剂量均显著增加了相对于 O 组的 BMD 增加,并且组平均值也高于 S 组。脊椎和股骨颈的大多数骨转换组织形态计量学指标均显著低于巴利昔替尼治疗的 O 组,除骨膜骨形成率(Ps.BFR)显著升高外。股骨中段的 Ps.BFR 也因治疗而显著增加。

结论

巴利昔替尼部分预防了去卵巢引起的骨量变化,抑制了大多数部位的骨转换,并对骨膜骨形成产生了意外的刺激作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验